logo-loader
viewe-Therapeutics PLC

e-Therapeutics unveils fundraising plans to enable next stage of growth

The company is aiming to raise the cash through a combination of a placing, a subscription and a retail offer to investors

e-Therapeutics PLC - e-Therapeutics unveils fundraising plans to enable next stage of growth

e-Therapeutics PLC (LON:ETX) has unveiled plans to raise up to £12.4mln to fund its “next stage of growth and value creation” by expanding its drug discovery platform and asset pipeline.

In an announcement after the close on Tuesday, the biopharmaceutical firm said it will raise £6.3mln of the total in a placing through the issue of around 52.8mln new shares at 12p each, a 30% discount to its Tuesday closing price.

WATCH: e-Therapeutics PLC's Ali Mortazavi welcomes new fibrosis collaboration with Galapagos

Meanwhile, the company also announced a subscription to raise around £2.8mln through the issue of 23.3mln new shares at the same price and a broker option to raise another £2.5mln.

The group also made a retail offer at the 12p price on the PrimaryBid platform to provide certain existing retail shareholders and other retail investors with an opportunity to participate in the fundraise. In an announcement on Wednesday morning, e-Therapeutics said the retail offer had raised £750,000 through the issue of 6.25mln shares.

e-Therapeutics said the proceeds of the combined fundraising will facilitate a number of initiatives including further development of the company’s informatics platform and building a proprietary platform for its RNAi technology.

The firm also said it plans to build and populate an internal pipeline of two to three early assets over the next 18 months, as well as expanding its team to support a scale-up of the business and relocating its head office in Oxford and opening a new base in London.

"I am excited by the potential of e-therapeutics' proprietary platform technologies to meaningfully transform and accelerate the drug discovery process, increasing the probability of bringing better therapies to market. The proposed fundraise will allow us to further invest in these and to expand our in-house capabilities and team. We believe that this will enable us to forge additional collaborations with leading biopharmaceutical companies”, e-Therapeutics executive chairman Ali Mortazavi said in a statement.

“It will also permit us to begin building our own pipeline against carefully selected targets, which could accrue, over time, significant additional value for the company and generate out-licensing opportunities. In particular, and as we have recently stated, we believe RNAi is a key modality that is well suited to our business and we will use part of the funds raised to explore translating our learnings from GAINs outcomes into targeted therapeutic strategies using this approach. We are grateful for the support of our existing and new shareholders and look forward to delivering value from our platform", the chairman added.

Quick facts: e-Therapeutics PLC

Price: 11.98 GBX

AIM:ETX
Market: AIM
Market Cap: £50.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 makes early rally as airline losses set to total...

Headlines from the Proactive UK newsroom. The FTSE 100 rallied early on after two days of losses with travel groups leading the way. The blue-chip index was up 30 points at 6,366. Airline losses will total around US$84bn this year according to the International Air Transport Association....

on 10/6/20

3 min read